https://www.oakhillbio.com https://www.oakhillbio.com/our-team https://www.oakhillbio.com/pipeline https://www.oakhillbio.com/press https://www.oakhillbio.com/privacy-notice https://www.oakhillbio.com/footprints https://www.oakhillbio.com/our-programs https://www.oakhillbio.com/expanded-access https://www.oakhillbio.com/news/2022-rbc-capital-markets-global-healthcare-conference https://www.oakhillbio.com/news/chiesi-group-and-oak-hill-bio-announce-license-and-development-agreement-to-develop-manufacture-and-commercialize-ohb-607-a-potentially-transformative-neonatal-therapy https://www.oakhillbio.com/news/oak-hill-bio-and-chiesi-enroll-first-patients-in-australia-and-japan-in-the-ohb-607-multinational-phase-2b-study-for-bpd-prevention https://www.oakhillbio.com/news/oak-hill-bio-and-chiesi-group-announce-first-european-patient-enrolled-in-the-phase-2b-clinical-study-evaluating-ohb-607-for-the-prevention-of-bronchopulmonary-dysplasia-in-premature-infants https://www.oakhillbio.com/news/oak-hill-bio-and-chiesi-group-announce-first-patient-enrolled-in-the-resumed-phase-2b-clinical-study-evaluating-ohb-607-for-the-prevention-of-bronchopulmonary-dysplasia-in-premature-infants https://www.oakhillbio.com/news/oak-hill-bio-announces-promotion-of-josh-distler-to-chief-executive-officer-and-additional-updates-to-executive-team-and-board https://www.oakhillbio.com/news/oak-hill-bio-announces-publication-of-rugonersen-phase-1-study-results-in-nature-medicine https://www.oakhillbio.com/news/oak-hill-bio-enters-into-exclusive-license-agreement-with-roche-to-obtain-global-rights-for-a-phase-3-ready-potential-best-in-class-treatment-for-individuals-with-angelman-syndrome https://www.oakhillbio.com/news/oak-hill-bio-joins-c-paths-international-neonatal-consortium https://www.oakhillbio.com/news/oak-hill-bio-launches https://www.oakhillbio.com/news/oak-hill-bio-sponsors-industry-symposium-at-international-conference-on-clinical-neonatology https://www.oakhillbio.com/news/oak-hill-bio-spotlights-publication-detailing-discovery-and-initial-development-of-rugonersen-in-nucleic-acids-research https://www.oakhillbio.com/news/oak-hill-bio-to-participate-in-2022-wells-fargo-private-biotech-symposium https://www.oakhillbio.com/news/oak-hill-bio-to-participate-in-citi-17th-annual-biopharma-conference https://www.oakhillbio.com/news/oak-hill-bio-to-present-at-2022-rbc-capital-markets-global-healthcare-conference https://www.oakhillbio.com/programs/ohb-401 https://www.oakhillbio.com/programs/ohb-607 https://www.oakhillbio.com/programs/rugonersen https://www.oakhillbio.com/board-of-directors/david-colpman https://www.oakhillbio.com/board-of-directors/hussein-al-mossawi https://www.oakhillbio.com/board-of-directors/jiaping-gu https://www.oakhillbio.com/board-of-directors/josh-distler https://www.oakhillbio.com/board-of-directors/kim-davis https://www.oakhillbio.com/board-of-directors/mark-mchale https://www.oakhillbio.com/team/ike-greenstein https://www.oakhillbio.com/team/josh-distler https://www.oakhillbio.com/team/mark-mchale https://www.oakhillbio.com/team/sharon-morriss https://www.oakhillbio.com/team/victoria-niklas